Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events
Sponsor: Beijing Institute of Heart, Lung and Blood Vessel Diseases
A observational or N/A phase clinical study on Essential Hypertension, this trial is ongoing. The trial is conducted by Beijing Institute of Heart, Lung and Blood Vessel Diseases and has accumulated 6 data snapshots since 2016. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Recruiting
-
Jun 2019 — Jan 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Nov 2018 — Jun 2019 [monthly]
Not Yet Recruiting
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Institute of Heart, Lung and Blood Vessel Diseases
- Shanxi Medical University
For direct contact, visit the study record on ClinicalTrials.gov .